| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 3993 | 2018 |
| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 1793 | 2020 |
| Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma RN Amaria, SM Reddy, HA Tawbi, MA Davies, MI Ross, IC Glitza, ... Nature medicine 24 (11), 1649-1654, 2018 | 719 | 2018 |
| Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ... Science 374 (6575), 1632-1640, 2021 | 462 | 2021 |
| Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) AM Menzies, RN Amaria, EA Rozeman, AC Huang, MT Tetzlaff, ... Nature medicine 27 (2), 301-309, 2021 | 290 | 2021 |
| Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised … RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ... The Lancet Oncology 19 (2), 181-193, 2018 | 281 | 2018 |
| Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ... Nature medicine 27 (8), 1432-1441, 2021 | 273 | 2021 |
| Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium RN Amaria, AM Menzies, EM Burton, RA Scolyer, MT Tetzlaff, ... The Lancet Oncology 20 (7), e378-e389, 2019 | 205 | 2019 |
| Neoadjuvant relatlimab and nivolumab in resectable melanoma RN Amaria, M Postow, EM Burton, MT Tetzlaff, MI Ross, C Torres-Cabala, ... Nature 611 (7934), 155-160, 2022 | 177 | 2022 |
| Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy R Somasundaram, T Connelly, R Choi, H Choi, A Samarkina, L Li, ... Nature communications 12 (1), 346, 2021 | 133 | 2021 |
| The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors CN Spencer, V Gopalakrishnan, J McQuade, MC Andrews, B Helmink, ... Cancer Research 79 (13_Supplement), 2838-2838, 2019 | 82 | 2019 |
| Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit D Grossman, N Okwundu, EK Bartlett, MA Marchetti, M Othus, DG Coit, ... JAMA dermatology 156 (9), 1004-1011, 2020 | 78 | 2020 |
| Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy CP Vellano, MG White, MC Andrews, M Chelvanambi, RG Witt, ... Nature 606 (7915), 797-803, 2022 | 71 | 2022 |
| Hallmarks of resistance to immune-checkpoint inhibitors M Karasarides, AP Cogdill, PB Robbins, M Bowden, EM Burton, ... Cancer immunology research 10 (4), 372-383, 2022 | 48 | 2022 |
| Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. RN Amaria, MA Postow, MT Tetzlaff, MI Ross, IC Glitza, JL McQuade, ... Journal of Clinical Oncology 39 (15_suppl), 9502-9502, 2021 | 46 | 2021 |
| Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). AM Menzies, EA Rozeman, RN Amaria, ACC Huang, RA Scolyer, ... Journal of Clinical Oncology 37 (15_suppl), 9503-9503, 2019 | 44 | 2019 |
| Neoadjuvant systemic therapy (NAST) in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC) ACJ van Akkooi, TJ Hieken, EM Burton, C Ariyan, PA Ascierto, ... Annals of surgical oncology 29 (6), 3694-3708, 2022 | 31 | 2022 |
| Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T)[TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): a … EM Burton, RN Amaria, IC Glitza, M Shephard, A Diab, D Milton, S Patel, ... Annals of Oncology 30, v534-v535, 2019 | 29 | 2019 |
| Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results IC Glitza Oliva, SD Ferguson, R Bassett Jr, AP Foster, I John, ... Nature medicine 29 (4), 898-905, 2023 | 28 | 2023 |
| Phase II Study of TRIplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T)(TRIDeNT) in patients (pts) with PD-1 naïve or refractory BRAF-mutated metastatic … EM Burton, RN Amaria, IC Glitza, DR Milton, A Diab, SP Patel, ... Journal of Clinical Oncology 39 (15_suppl), 9520-9520, 2021 | 28 | 2021 |
